

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7






FIG. 8a



pA2HG1apgpt

FIG. 8b



pA2HuKapgpt

FIG. 9a




FIG. 9b




FIG. 10a




FIG. 10b




FIG. 11




FIG. 12




FIG. 13

| | | |
|-----|---|-----|
| 1 | Val Arg Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro | 10 |
| 21 | Gln Ala Glu Gly Gln Leu Cln Trp Leu Asn Arg Arg Ala Asn Ala Leu Ala Asn Gly | 30 |
| 41 | Val Glu Leu Arg Asp Asn Gln Leu Val Val pro Ser Glu Gly Leu Tyr Leu Ile Tyr Ser | 50 |
| 61 | Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile | 70 |
| 81 | Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro | 90 |
| 101 | Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr Leu | 110 |
| 121 | Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp | 130 |
| 141 | Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu | 150 |

FIG. 14a




FIG. 14b





FIG. 15

1 Val Arg Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro
10
21 Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Leu Ala Asn Gly
30
41 Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser Glu Gly Leu Tyr Leu Ile Tyr Ser
50
61 Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile
70
81 Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro
90
101 Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr Leu
110
121 Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp
130
141 Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu
150

FOUO 07/24/2000

Figure 16



Docket No.: 0975.1005-012
Title: Anti-TNF Antibodies and Peptides...
Inventors: Junming Le, *et al.*

Figure 17A

CA2 LIGHT CHAIN VARIABLE REGION SEQUENCE

GACATCTTGCTGACTCAGTCTCCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCAGT
AspIleLeuLeuThrGlnSerProAlaIleLeuSerValSerProGlyGluArgValSer

TTCTCCTGCACGGCCAGTCAGTTCGTTGGCTCAAGCATCCACTGCTATCAGCAAAGAACA
PheSerCysArgAlaSerGlnPheValGlySerSerIleHisTrpTyrGlnGlnArgThr

AATCGTTCTCCAAGGCTTCTCATAAAGTATGCTTCTGAGTCTATGTCTGGGATCCCTTCC
AsnGlySerProArgLeuLeuIleLysTyrAlaSerGluSerMetSerGlyIleProSer

AGCTTTAGTGGCAGTGGATCAGGGACAGATTTTACTGTTAGCATCAAGACTGTGCACTGT
ArgPheSerGlySerGlySerGlyThrAspPheThrLeuSerIleAsnThrValGluSer

GAAGATATTGCAGATTATTACTGTCAAGAAAGTCATAGCTCCCCATTACGTTCCGCTCG
GluAspIleAlaAspTyrTyrCysGlnGlnSerHisSerTrpProPheThrPheGlySer

CGGACAAATTTGCAAGTAAAA
GlyThrAsnLeuGluVallys

0975.1005-012

Docket No.: 0975.1005-012
Title: Anti-TNF Antibodies and Peptides...
Inventors: Junming Le, *et al.*

GAAGTCAAGCTTCAGCACTCTGCACCACCCCTTCCTGCAACCTCCAGCATCCATCAAACCTC
GluValLysLeuGluGluSerGlyGlyGlyLeuValGlnProGlyGlySerMetLysLeu

TCCTGTGTTGCCTCTGGATTCAATTTTCAGTAACCACTGGATGAACTGGGTCCGCCAGTCT
SerCysValAlaSerGlyPheIlePheSerAsnHisTrpMetAsnTrpValArgGlnSer

CCACAGAAGGGGCTTGAGTGGGTGCTCAAATTAGATCAAAATCTATTAATTCTGCAACA
ProGluLysGlyLeuGluTrpValAlaGluIleArgSerLysSerIleAsnSerAlaThr

CATTATCGCGAGTCTGTGAAAGGGAGGTTCAACATCTCAAGAGATGATTCCAAAAGTGCT
HisTyrAlaGluSerValLysGlyArgPheThrIleSerArgAspAspSerLysSerAla

GTCTACCTGCAAATGACCGACTTAAGAACTGAAGACACTGCGGTTTATTACTGTTCAGG
ValTyrLeuGlnMetThrAspLeuArgThrGluAspThrGlyValTyrTyrCysSerArg

AATTACTACGGTAGTACCTACGACTACTCGGGCCAAGGCACCACTCTCACAGTCTCC
AsnTyrTyrGlySerThrTyrAspTyrTrpGlyGlnGlyThrThrLeuThrValSer

Figure 17B

0975.1005-012

anti-TNF Trial

EMS




FIG-18

anti-TNF Trial

Pain




FIG. 19

anti-TNF Trial

Ritchie Articular Index




FIG. 20

anti-TNF Trial

Swollen Joints




FIG 21

anti-TNF Trial

CRP




FIG. 22

anti-TNF Trial

ESR




FIG 23

anti-TNF Trial

Index of Disease Activity




FIG 24

SWOLLEN JOINT COUNTS IN PATIENTS WITH RA FOLLOWING CA2 ADMINISTRATION




FIGURE 25

EFFECT OF cA2 ADMINISTRATION ON CRP LEVELS IN PATIENTS WITH RA





FIGURE 2.6

27

A



JC K gene

27

B




FIGURE 27A-B




FIGURE 28




FIGURE 29




FIGURE 30




FIGURE 31




FIGURE 32

A)




FIGURE 33 A

B)




FIGURE 33 B

C)




FIGURE 33 C






FIGURE 34



FIGURE

35 A



FIGURE

35 B